>85%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
<0.10 EU per 1 μg of the protein by the LAL method.
Measured in an anti-viral assay using HepG2 human hepatocellular carcinoma cells infected with encephalomyocarditis (EMC) virus. Sheppard, P. et al. (2003) Nat. Immunol. 4:63. The ED50 for this effect is 0.2-1.2 μg/mL.
E. coli-derived human IFN-lambda 4 protein Ala23-Leu179 with an N-terminal Met
Recombinant Human IFN-lambda 4 (Catalog # 9165-IF) exhibits anti-viral activity in HepG2human hepatocellular carcinoma cells infected with encephalomyocarditis (EMC)virus. The ED50 for this effect is 0.2-1.2 μg/mL.
Background: IFN-lambda 4
Interferon-lambda 4 (IFN-lambda 4) is a secreted, approximately 17 kDa member
of the type III interferon family of molecules (1). It is generated by a
frameshift mutation based on a TT > ∆G polymorphism (2). The TT
allele inactivates expression of IFN-lambda 4 (2). The ∆G allele is
associated with reduced clearance of hepatitis C virus and reduced
degranulation of CTL, NK, and NKT cells in the liver during hepatitis
(2, 3), although IFN- lambda 4 itself shows in vitro
activity against hepatitis C virus (4). IFN-lambda 4 is expressed in the
liver of some chronic hepatitis C patients (5). It signals through a
receptor complex containing IL-28 R/IFN-lambda R1 and IL-10 R beta to induce the
expression of several interferon stimulated genes (ISG) (2, 4).
Alternative splicing generates additional isoforms with large internal
deletions or a substituted C-terminal region.
Wack, A. et al. (2015) Nat. Immunol. 16:802.
Prokunina-Olsson, L. et al. (2013) Nat. Genet. 45:164.
Jouvin-Marche, E. et al. (2014) J. Infec. Dis. 209:1907.
Have you used Recombinant Human IFN-lambda 4 Protein, CF?
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.